{"id":"NCT01808313","sponsor":"GlaxoSmithKline","briefTitle":"Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)","officialTitle":"An Open Label Phase IIIb Study to Evaluate Efficacy and Safety of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12-01","primaryCompletion":"2014-08-15","completion":"2014-08-15","firstPosted":"2013-03-11","resultsPosted":"2015-05-12","lastUpdate":"2017-06-06"},"enrollment":134,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Vascular Disease"],"interventions":[{"type":"DRUG","name":"ambrisentan","otherNames":[]}],"arms":[{"label":"ambrisentan","type":"EXPERIMENTAL"}],"summary":"This open label, single-arm, non-controlled, multicentre study will determine the effect of ambrisentan on exercise capacity (6MWT) in Chinese subjects with PAH. The study consists of a screening period of 4 weeks, a 12-week primary evaluation period (PEP) and a 12-week dose-adjustment period (DAP). Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks (PEP).","primaryOutcome":{"measure":"Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Ambrisentan","deltaMin":53.59,"sd":64.494}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":17},"locations":{"siteCount":12,"countries":["China"]},"refs":{"pmids":["32799568","32680480","27770771"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":134},"commonTop":["Oedema peripheral","Flushing","Alanine aminotransferase increased","Aspartate aminotransferase increased","Blood bilirubin increased"]}}